Veryan gets $1.2m boost:
This article was originally published in Clinica
Vascular graft specialist Veryan Medical has secured an additional £620,000 ($1.2m) from existing investor Imperial Innovations, bringing their total investment received to date to £3.1m. Other investors in the start-up include NESTA (National Endowment for Science, Technology and the Arts), Nikko Principal Investments and Oxford Capital Partners. Veryan, of Horsham, UK, intends to use the funding to finance the addition of a range of proprietary Swirlflow vascular stents. The technology incorporates a 3D helical design to recreate the natural swirling blood flow in an artery, thereby reducing restenosis.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.